Engineered Bacteria for Gut Inflammation via Environmental Gene Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) and autoimmune disorders often involve systemic immunosuppression, which comes with side effects like increased susceptibility to infections and cancer, and alternative methods like fecal transfer raise safety concerns and stigma, while genetically engineered microbes that produce anti-inflammatory molecules have shown limited efficacy due to viability and stability issues.
Innovation Solution
Genetically engineered bacteria that produce therapeutic molecules like butyrate are designed to be functionally silent until they reach the gut, where they are induced to produce anti-inflammatory and gut barrier-enhancing compounds, using environmental conditions such as oxygen levels or reactive species to control gene expression, ensuring localized treatment and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic immunosuppression is used to treat IBD, then inflammation is reduced, but susceptibility to infections and cancer increases
Solution Approach 1:
The patent applies local quality by delivering anti-inflammatory molecules specifically to the gut lumen through engineered bacteria, rather than systemically. The bacteria produce and secrete therapeutic molecules (e.g., butyrate, IL-10, IL-22) locally at the site of inflammation, reducing gut inflammation while avoiding systemic immunosuppression and its associated risks of increased infection and cancer susceptibility.
Solution Approach 2:
The engineered bacteria serve as an intermediary vehicle to deliver therapeutic molecules to the gut. These bacteria carry genes that encode anti-inflammatory proteins and release them in the gut lumen, acting as a mediator between the therapeutic agent and the target tissue, thereby achieving localized treatment without systemic side effects.
2Reliability
If fecal transfer is used to treat IBD, then gut barrier function is improved, but safety concerns and stigma arise
Solution Approach 1:
The patent extracts the beneficial functional components (butyrate production, anti-inflammatory molecule secretion) from the complex fecal matter and isolates them into specifically engineered bacterial strains. This allows the therapeutic effects to be delivered without the safety concerns and stigma associated with fecal transfer, as the bacteria are laboratory-generated rather than donor-derived.
Solution Approach 2:
The engineered bacteria are created by copying and modifying specific genetic functions (butyrate synthesis pathways, anti-inflammatory gene expression) in a controlled laboratory setting. This synthetic approach replicates the beneficial effects of fecal transfer without the risks of transmitting pathogens or other unwanted substances from donors.
3Ease of operation
If genetically engineered microbes are used to produce anti-inflammatory molecules, then localized treatment is achieved, but viability and stability issues limit efficacy
Solution Approach 1:
The patent employs dynamic control of gene expression using environmental sensors that respond to gut conditions. The bacteria are engineered with promoters that are activated only under specific conditions (e.g., low oxygen, presence of inflammatory cytokines), allowing them to remain stable during transit and only produce therapeutic molecules when needed in the inflamed gut environment, thereby improving both viability and functional stability.
Solution Approach 2:
The engineered bacteria utilize environmental parameter changes (oxygen levels, pH, presence of inflammatory markers) to regulate their therapeutic output. By linking gene expression to these physical and chemical parameters of the gut environment, the bacteria maintain stability during transport and activation only when the gut conditions indicate the need for therapeutic intervention, thus improving reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bacteria effectively reduce gut inflammation and enhance gut barrier function, potentially treating or preventing IBD and autoimmune disorders with reduced systemic side effects and improved safety profiles.
Implementation Method 1
therapeutic molecules under the control of one or more promoters induced by an environmental condition, e.g., an environmental condition found in the mammalian gut, such as an inflammatory condition or a low oxygen condition
Implementation Method 2
butyrate is normally produced by microbial fermentation of dietary fiber and plays a central role in maintaining colonic epithelial cell homeostasis and barrier function
Implementation Method 3
promoters induced by inflammation or an inflammatory response (RNS, ROS promoters)
Data Source
AI summary
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.